Biomedical Advanced Research and Development Authority (BARDA) Supports Development of New Drugs to Treat Radiation Injury Through Contracts with Apogee Biotechnology Corporation and Avaxia Biologics

WASHINGTON--(BUSINESS WIRE)--The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).
MORE ON THIS TOPIC